Sitryx Therapeutics

Executive Summary

Sitryx Therapeutics is a preclinical biopharmaceutical company pioneering the regulation of immune cell metabolism to treat autoimmune diseases, inflammatory disorders, and cancer. Founded in 2018 and headquartered in Boston, the company emerged from leading academic research in immunometabolism, targeting metabolic pathways in immune cells to restore immune homeostasis or inhibit tumor growth. With $39 million raised to date, Sitryx is advancing a pipeline of small molecule modulators aimed at key metabolic checkpoints. Its platform addresses the growing recognition that metabolic dysfunction underlies many immune-mediated diseases, positioning the company at the forefront of a promising therapeutic area. The company's lead programs focus on autoimmune and inflammatory indications, with plans to enter clinical trials in the near term. Sitryx's approach offers potential for disease-modifying outcomes rather than just symptom relief, appealing to a large market opportunity. However, as a preclinical stage company, it faces significant technical and regulatory risks, including the challenge of translating metabolic modulation from bench to bedside. The company's ability to secure additional financing and demonstrate preclinical proof-of-concept will be critical for de-risking its pipeline and attracting partnerships.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead Autoimmune Program40% success
• Q4 2026Series B Financing Round60% success
• Q3 2026Presentation of Preclinical Data at Major Conference80% success